Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

RXR-Selective retinoid, Bexarotene (Targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic leukemia (CLL) cells to Denileukin diftitox (ONTAK)

RXR-Selective retinoid, Bexarotene (Targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic leukemia (CLL) cells to Denileukin diftitox (ONTAK). RXR-Selective retinoid, Bexarotene (Targretin) upregulates IL2R expression and enhances sensitivity of B-chronic lymphocytic leukemia (CLL) cells to Denileukin diftitox (ONTAK). 2001; 91(11a, Suppl. ):150a.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.